 David Morrison
Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cataract Extraction | 12 | 2024 | 120 | 2.350 |
Why?
| | Ophthalmology | 10 | 2024 | 116 | 2.310 |
Why?
| | Lens Implantation, Intraocular | 12 | 2024 | 80 | 2.090 |
Why?
| | Aphakia, Postcataract | 9 | 2024 | 13 | 1.780 |
Why?
| | Retinopathy of Prematurity | 8 | 2024 | 180 | 1.570 |
Why?
| | Cataract | 12 | 2024 | 212 | 1.460 |
Why?
| | Oculomotor Muscles | 10 | 2022 | 86 | 1.420 |
Why?
| | Amblyopia | 6 | 2023 | 60 | 1.320 |
Why?
| | Ophthalmologic Surgical Procedures | 9 | 2022 | 90 | 1.270 |
Why?
| | Strabismus | 8 | 2021 | 71 | 1.240 |
Why?
| | Academies and Institutes | 6 | 2024 | 58 | 1.140 |
Why?
| | Visual Acuity | 18 | 2024 | 491 | 0.960 |
Why?
| | Contact Lenses | 3 | 2015 | 13 | 0.910 |
Why?
| | Pseudophakia | 6 | 2024 | 21 | 0.870 |
Why?
| | Tardive Dyskinesia | 1 | 2023 | 2 | 0.800 |
Why?
| | Exotropia | 4 | 2023 | 25 | 0.760 |
Why?
| | Lacrimal Duct Obstruction | 2 | 2020 | 11 | 0.730 |
Why?
| | Nasolacrimal Duct | 2 | 2020 | 12 | 0.730 |
Why?
| | Eye Movements | 5 | 2022 | 93 | 0.680 |
Why?
| | Dacryocystorhinostomy | 1 | 2020 | 13 | 0.660 |
Why?
| | Myopia | 3 | 2024 | 59 | 0.590 |
Why?
| | Vision, Binocular | 5 | 2021 | 47 | 0.570 |
Why?
| | Angiogenesis Inhibitors | 2 | 2018 | 238 | 0.540 |
Why?
| | Nystagmus, Pathologic | 3 | 2023 | 19 | 0.540 |
Why?
| | Refraction, Ocular | 4 | 2024 | 47 | 0.530 |
Why?
| | Laser Coagulation | 1 | 2018 | 79 | 0.520 |
Why?
| | Eye Diseases | 1 | 2018 | 95 | 0.500 |
Why?
| | Corneal Endothelial Cell Loss | 1 | 2015 | 3 | 0.460 |
Why?
| | Posture | 4 | 2022 | 197 | 0.460 |
Why?
| | Glaucoma | 5 | 2021 | 247 | 0.430 |
Why?
| | Sensory Deprivation | 2 | 2023 | 17 | 0.420 |
Why?
| | Head | 3 | 2020 | 120 | 0.420 |
Why?
| | Fixation, Ocular | 2 | 2014 | 28 | 0.410 |
Why?
| | Infant | 23 | 2024 | 10023 | 0.390 |
Why?
| | Gestational Age | 6 | 2020 | 980 | 0.390 |
Why?
| | Follow-Up Studies | 15 | 2024 | 5414 | 0.370 |
Why?
| | Neonatal Screening | 4 | 2020 | 179 | 0.370 |
Why?
| | Persistent Hyperplastic Primary Vitreous | 1 | 2011 | 1 | 0.350 |
Why?
| | Lenses, Intraocular | 4 | 2021 | 49 | 0.340 |
Why?
| | Eye Diseases, Hereditary | 2 | 2021 | 15 | 0.320 |
Why?
| | Depth Perception | 1 | 2010 | 5 | 0.310 |
Why?
| | Telemedicine | 2 | 2016 | 957 | 0.310 |
Why?
| | Nystagmus, Congenital | 2 | 2020 | 4 | 0.310 |
Why?
| | Postoperative Complications | 6 | 2024 | 2950 | 0.300 |
Why?
| | Child | 23 | 2024 | 22600 | 0.270 |
Why?
| | Retrospective Studies | 20 | 2024 | 17149 | 0.270 |
Why?
| | Infant, Newborn | 12 | 2024 | 6399 | 0.260 |
Why?
| | Humans | 48 | 2024 | 144667 | 0.260 |
Why?
| | Technology Assessment, Biomedical | 3 | 2021 | 44 | 0.250 |
Why?
| | Tenotomy | 3 | 2019 | 22 | 0.230 |
Why?
| | Synkinesis | 1 | 2005 | 1 | 0.230 |
Why?
| | Anterior Chamber | 1 | 2005 | 26 | 0.220 |
Why?
| | Oculomotor Nerve Diseases | 1 | 2005 | 14 | 0.220 |
Why?
| | Marfan Syndrome | 1 | 2005 | 46 | 0.220 |
Why?
| | Mydriatics | 1 | 2005 | 10 | 0.220 |
Why?
| | Diagnostic Techniques, Ophthalmological | 2 | 2016 | 53 | 0.220 |
Why?
| | Atropine | 1 | 2005 | 37 | 0.220 |
Why?
| | Myopia, Degenerative | 1 | 2024 | 5 | 0.220 |
Why?
| | Contact Lenses, Hydrophilic | 1 | 2024 | 7 | 0.220 |
Why?
| | Lens, Crystalline | 1 | 2005 | 83 | 0.210 |
Why?
| | Child, Preschool | 15 | 2024 | 11790 | 0.210 |
Why?
| | Anisometropia | 2 | 2022 | 18 | 0.210 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2024 | 23 | 0.200 |
Why?
| | Carbidopa | 1 | 2023 | 11 | 0.200 |
Why?
| | Levodopa | 1 | 2023 | 41 | 0.200 |
Why?
| | Fetal Diseases | 1 | 2005 | 193 | 0.190 |
Why?
| | Photorefractive Keratectomy | 1 | 2022 | 21 | 0.180 |
Why?
| | Tendons | 2 | 2014 | 129 | 0.180 |
Why?
| | Laser Therapy | 1 | 2024 | 140 | 0.180 |
Why?
| | United States | 8 | 2024 | 16018 | 0.180 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2018 | 550 | 0.170 |
Why?
| | Orthoptics | 1 | 2021 | 2 | 0.170 |
Why?
| | Accommodation, Ocular | 1 | 2021 | 15 | 0.170 |
Why?
| | Exome | 1 | 2022 | 227 | 0.170 |
Why?
| | Esotropia | 2 | 2012 | 29 | 0.170 |
Why?
| | Infant, Extremely Low Birth Weight | 2 | 2018 | 24 | 0.170 |
Why?
| | Vision Disorders | 2 | 2020 | 179 | 0.160 |
Why?
| | Ocular Motility Disorders | 1 | 2021 | 42 | 0.160 |
Why?
| | Treatment Outcome | 11 | 2021 | 11735 | 0.160 |
Why?
| | Eye Injuries | 1 | 2021 | 53 | 0.160 |
Why?
| | Neuromuscular Agents | 1 | 2021 | 45 | 0.160 |
Why?
| | Drug Therapy, Combination | 1 | 2023 | 1044 | 0.160 |
Why?
| | Suture Techniques | 1 | 2021 | 137 | 0.160 |
Why?
| | Botulinum Toxins, Type A | 1 | 2021 | 58 | 0.160 |
Why?
| | Papilledema | 1 | 2020 | 44 | 0.150 |
Why?
| | Optic Nerve Diseases | 1 | 2020 | 49 | 0.150 |
Why?
| | Optic Disk | 1 | 2020 | 53 | 0.150 |
Why?
| | Adolescent | 13 | 2024 | 22409 | 0.150 |
Why?
| | Bevacizumab | 2 | 2018 | 168 | 0.150 |
Why?
| | Birth Weight | 2 | 2020 | 506 | 0.150 |
Why?
| | Retinal Ganglion Cells | 1 | 2020 | 115 | 0.150 |
Why?
| | Fluorescein Angiography | 1 | 2020 | 190 | 0.140 |
Why?
| | Cornea | 2 | 2022 | 154 | 0.140 |
Why?
| | Disease Progression | 4 | 2024 | 2847 | 0.140 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2019 | 73 | 0.140 |
Why?
| | Vitreous Hemorrhage | 1 | 2018 | 10 | 0.140 |
Why?
| | Hyphema | 1 | 2018 | 6 | 0.140 |
Why?
| | Male | 22 | 2024 | 72431 | 0.140 |
Why?
| | Tomography, Optical Coherence | 1 | 2020 | 270 | 0.130 |
Why?
| | Intravitreal Injections | 1 | 2018 | 71 | 0.130 |
Why?
| | Hyperopia | 2 | 2024 | 19 | 0.130 |
Why?
| | Corneal Diseases | 1 | 2018 | 46 | 0.130 |
Why?
| | Female | 23 | 2024 | 78304 | 0.130 |
Why?
| | Sensitivity and Specificity | 3 | 2016 | 1995 | 0.130 |
Why?
| | Ophthalmoscopy | 1 | 2016 | 38 | 0.120 |
Why?
| | Prospective Studies | 8 | 2024 | 7994 | 0.120 |
Why?
| | Corneal Pachymetry | 1 | 2015 | 16 | 0.110 |
Why?
| | Endothelium, Corneal | 1 | 2015 | 18 | 0.110 |
Why?
| | Health Plan Implementation | 1 | 2016 | 141 | 0.110 |
Why?
| | Eye Neoplasms | 1 | 2015 | 30 | 0.110 |
Why?
| | Infant, Premature | 1 | 2020 | 614 | 0.110 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 26 | 0.110 |
Why?
| | Uveitis, Anterior | 1 | 2015 | 27 | 0.110 |
Why?
| | Conjunctiva | 1 | 2015 | 52 | 0.110 |
Why?
| | Iris | 2 | 2024 | 23 | 0.110 |
Why?
| | Cell Count | 1 | 2015 | 320 | 0.110 |
Why?
| | Tensile Strength | 1 | 2014 | 98 | 0.100 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 89 | 0.100 |
Why?
| | Video Recording | 2 | 2012 | 217 | 0.100 |
Why?
| | Child Development | 1 | 2018 | 482 | 0.100 |
Why?
| | Diagnostic Imaging | 1 | 2016 | 341 | 0.100 |
Why?
| | Acute Disease | 1 | 2016 | 1029 | 0.100 |
Why?
| | Vision Screening | 2 | 2010 | 48 | 0.090 |
Why?
| | Stress, Mechanical | 1 | 2014 | 494 | 0.090 |
Why?
| | Vision Tests | 2 | 2023 | 22 | 0.090 |
Why?
| | Incidence | 4 | 2021 | 2892 | 0.080 |
Why?
| | Intraocular Pressure | 2 | 2024 | 326 | 0.080 |
Why?
| | Fatal Outcome | 2 | 2015 | 305 | 0.080 |
Why?
| | Fovea Centralis | 1 | 2010 | 24 | 0.080 |
Why?
| | Intubation | 1 | 2008 | 7 | 0.070 |
Why?
| | Eyeglasses | 2 | 2023 | 24 | 0.070 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3414 | 0.070 |
Why?
| | Cohort Studies | 4 | 2024 | 5957 | 0.070 |
Why?
| | Intraoperative Complications | 2 | 2019 | 157 | 0.070 |
Why?
| | Preoperative Care | 1 | 2010 | 379 | 0.060 |
Why?
| | Registries | 3 | 2020 | 2392 | 0.060 |
Why?
| | Reoperation | 2 | 2020 | 624 | 0.060 |
Why?
| | Risk Factors | 5 | 2021 | 10796 | 0.060 |
Why?
| | Infant, Very Low Birth Weight | 2 | 2016 | 74 | 0.060 |
Why?
| | Recovery of Function | 1 | 2010 | 715 | 0.060 |
Why?
| | Oculomotor Nerve | 1 | 2005 | 9 | 0.060 |
Why?
| | Eye Injuries, Penetrating | 1 | 2005 | 19 | 0.060 |
Why?
| | Isotretinoin | 1 | 2005 | 26 | 0.060 |
Why?
| | Acne Vulgaris | 1 | 2005 | 25 | 0.050 |
Why?
| | Eyelids | 1 | 2005 | 41 | 0.050 |
Why?
| | Emmetropia | 1 | 2024 | 1 | 0.050 |
Why?
| | Vitrectomy | 1 | 2005 | 73 | 0.050 |
Why?
| | Administration, Topical | 1 | 2005 | 152 | 0.050 |
Why?
| | Corpus Callosum | 1 | 2005 | 72 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2010 | 2922 | 0.050 |
Why?
| | Iridectomy | 1 | 2024 | 2 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2117 | 0.050 |
Why?
| | Treatment Refusal | 1 | 2005 | 98 | 0.050 |
Why?
| | Adult | 6 | 2022 | 40489 | 0.050 |
Why?
| | Maternal Exposure | 1 | 2005 | 185 | 0.050 |
Why?
| | Cerebellum | 1 | 2005 | 224 | 0.050 |
Why?
| | Toll-Like Receptor 7 | 1 | 2022 | 43 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1505 | 0.050 |
Why?
| | Lasers, Excimer | 1 | 2022 | 30 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2005 | 1268 | 0.040 |
Why?
| | Physicians' Offices | 1 | 2021 | 18 | 0.040 |
Why?
| | Sutures | 1 | 2021 | 65 | 0.040 |
Why?
| | Injections, Intramuscular | 1 | 2021 | 144 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1742 | 0.040 |
Why?
| | Genetic Testing | 1 | 2023 | 480 | 0.040 |
Why?
| | Chin | 1 | 2020 | 8 | 0.040 |
Why?
| | Fundus Oculi | 1 | 2020 | 89 | 0.040 |
Why?
| | Planning Techniques | 1 | 2019 | 15 | 0.040 |
Why?
| | Nerve Fibers | 1 | 2020 | 105 | 0.040 |
Why?
| | Refractive Errors | 1 | 2019 | 36 | 0.040 |
Why?
| | Time Factors | 2 | 2021 | 7140 | 0.030 |
Why?
| | Home Care Services | 1 | 2021 | 280 | 0.030 |
Why?
| | Pilot Projects | 1 | 2023 | 1886 | 0.030 |
Why?
| | Canada | 1 | 2018 | 432 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 967 | 0.030 |
Why?
| | Patient Compliance | 1 | 2021 | 587 | 0.030 |
Why?
| | Aging | 1 | 2007 | 1938 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2021 | 707 | 0.030 |
Why?
| | Allied Health Personnel | 1 | 2016 | 55 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1374 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1501 | 0.030 |
Why?
| | Chronic Disease | 1 | 2021 | 1810 | 0.030 |
Why?
| | Leukemic Infiltration | 1 | 2015 | 11 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2022 | 3603 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 2114 | 0.030 |
Why?
| | Office Visits | 1 | 2014 | 92 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2350 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2016 | 287 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2005 | 3888 | 0.020 |
Why?
| | Weight Gain | 1 | 2016 | 557 | 0.020 |
Why?
| | Pregnancy | 1 | 2005 | 7122 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2016 | 1103 | 0.020 |
Why?
| | Corneal Opacity | 1 | 2011 | 8 | 0.020 |
Why?
| | Models, Statistical | 1 | 2016 | 677 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 638 | 0.020 |
Why?
| | Risk Assessment | 1 | 2021 | 3729 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2015 | 528 | 0.020 |
Why?
| | Observer Variation | 1 | 2011 | 355 | 0.020 |
Why?
| | Young Adult | 2 | 2021 | 14122 | 0.020 |
Why?
| | Injections, Intraocular | 1 | 2010 | 14 | 0.020 |
Why?
| | Vitreous Body | 1 | 2010 | 117 | 0.020 |
Why?
| | Lacrimal Apparatus Diseases | 1 | 2008 | 3 | 0.020 |
Why?
| | Tears | 1 | 2008 | 27 | 0.020 |
Why?
| | Fluorescein | 1 | 2008 | 24 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1844 | 0.020 |
Why?
| | Selection Bias | 1 | 2007 | 38 | 0.020 |
Why?
| | Device Removal | 1 | 2008 | 142 | 0.020 |
Why?
| | Age Distribution | 1 | 2007 | 402 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2008 | 333 | 0.020 |
Why?
| | Reference Values | 1 | 2007 | 794 | 0.010 |
Why?
| | Colorado | 1 | 2016 | 4558 | 0.010 |
Why?
| | Odds Ratio | 1 | 2007 | 1076 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 990 | 0.010 |
Why?
| | Patient Selection | 1 | 2007 | 727 | 0.010 |
Why?
| | Prevalence | 1 | 2010 | 2839 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2010 | 2942 | 0.010 |
Why?
| | Quality of Life | 1 | 2008 | 3183 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2008 | 6041 | 0.010 |
Why?
| | Animals | 1 | 2014 | 37948 | 0.010 |
Why?
|
|
Morrison's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|